The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.

Frontiers in Immunology
Katie HudsonRebecca Leyland

Abstract

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; ultimately preventing exacerbated activation and autoimmunity. Many tumors exploit this mechanism by overexpressing PD-L1 which often correlates with poor prognosis. Some tumors have also recently been shown to express PD-1. On tumors, PD-L1 binding to PD-1 on immune cells promotes immune evasion and tumor progression, primarily by inhibition of cytotoxic T lymphocyte effector function. PD-1/PD-L1-targeted therapy has revolutionized the cancer therapy landscape and has become the first-line treatment for some cancers, due to their ability to promote durable anti-tumor immune responses in select patients with advanced cancers. Despite this clinical success, some patients have shown to be unresponsive, hyperprogressive or develop resistance to PD-1/PD-L1-targeted therapy. The exact mechanisms for this are still unclear. This review will discuss the current status of PD-1/PD-L1-targeted therapy, oncogenic expression of PD-L1, the new and emerging tumor-intrinisic roles of PD-L1 and its receptor PD-1 and how they may contribute to tumor progression and immunoth...Continue Reading

References

Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takeo NomiYoshiyuki Nakajima
Jan 29, 2008·Blood·Takeshi AzumaLieping Chen
Sep 16, 2008·European Journal of Immunology·Candace M ChamThomas F Gajewski
Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yeong Seok KimDae Young Hur
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
May 11, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Samuel T HaileSuzanne Ostrand-Rosenberg
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Apr 3, 2012·Cell·Chi V Dang
Oct 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaofeng JiangF Stephen Hodi
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Nov 6, 2013·Annual Review of Medicine·David B PageJedd D Wolchok
Dec 4, 2013·Cancer Immunology, Immunotherapy : CII·Christian J MaineSadaf Ghaem-Maghami
Dec 18, 2013·Cancer Research·Ivraym B BarsoumCharles H Graham
Apr 26, 2014·Cancer Immunology Research·Elizabeth A MittendorfGheath Alatrash
Apr 30, 2014·The Journal of Experimental Medicine·Muhammad Zaeem NomanSalem Chouaib
May 21, 2014·Breast Cancer Research and Treatment·S MuenstS D Soysal
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory L Beatty, Whitney L Gladney
Jan 20, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yu FujitaTakahiro Ochiya
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-Seq
acetylation
ubiquitination
xenograft

Clinical Trials Mentioned

NCT01844505
NCT01642004
NCT01668784
NCT01592370
NCT02488759
NCT02387996
NCT02060188
NCT01658878
NCT01928394
NCT01866319

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.